Clostridium difficile infection: An emerging epidemic with more questions than answers

Future Microbiology

Volumn 5, Issue 8, 2010, Pages 1153-1156

  Dupont, Herbert L ^a,b,c,d   Garey, Kevin W ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b St Lukes Episcopal Hospital   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

C. difficile recurrence; C. difficile toxin; Clostridium difficile; fidaxomicin; rifaximin

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; CHLORHEXIDINE; FIDAXOMICIN; METRONIDAZOLE; PENICILLIN G; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SOAP; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIUM CONTAMINATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; EDITORIAL; ENZYME IMMUNOASSAY; EPIDEMIC; HAND WASHING; HOSPITAL HYGIENE; HUMAN; INFECTION RISK; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNICABLE DISEASES, EMERGING; CROSS INFECTION; DISEASE OUTBREAKS; HUMANS; RISK FACTORS;

CLOSTRIDIUM DIFFICILE;

EID: 77955945217     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.80     Document Type: Editorial

References (25)

1. Price MF, Dao-Tran T, Garey KW et al.: Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J. Hosp. Infect. 65, 22-26 (2007).
2. Bishara J, Peled N, Pitlik S, Samra Z: Mortality of patients with antibiotic-associated diarrhoea: the impact of Clostridium difficile. J. Hosp. Infect. 68, 208-214 (2008).
3. Surveillance for community-associated Clostridium difficile -Connecticut, 2006. MMWR Morb. Mortal. Wkly Rep. 57, 240-243 (2008).
4. Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM: Clostridium difficile in retail meat products, USA, 2007. Emerg. Infect. Dis. 15, 219-221 (2009).
5. Kyne L, Warny M, Qamar A, Kelly CP: Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 289-293 (2001).
6. Leav BA, Blair B, Leney M et al.: Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28, 265-269 (2010).
7. Lyras D, O'Connor JR, Howarth PM et al.: Toxin B is essential for virulence of Clostridium difficile. Nature 458, 2176-2179 (2009).
8. Garey KW, Sethi S, Yadav Y, DuPont HL: Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J. Hosp. Infect. 70, 298-304 (2008).
9. Jiang ZD, DuPont HL, Garey K et al.: A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am. J. Gastroenterol. 101, 2112-2116 (2006).
10. Jiang ZD, Garey KW, Price M et al.: Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin. Gastroenterol. Hepatol. 5, 264-268 (2007).
11. Eastwood K, Else P, Charlett A, Wilcox M: Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J. Clin. Microbiol. 47, 2211-2217
12. Huang H, Weintraub A, Fang H, Nord CE: Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. J. Clin. Microbiol. 47, 2729-2731 (2009).
13. Goldenberg SD, Cliff PR, Smith S, Milner M, French GL: Two-step glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J. Hosp. Infect. 74, 28-54
14. Debast SB, van Kregten E, Oskam KM, van den Berg T, Van den Berg RJ, Kuijper EJ: Effect on diagnostic yield of repeated stool testing during outbreaks of Clostridium difficile-associated disease. Clin. Microbiol. Infect. 14, 222-224 (2008).
15. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45, 202-207 (2007).
16. Henrich TJ, Krakower D, Bitton A, Yokoe DS: Clinical risk factors for severe Clostridium difficile-associated, disease. Emerg. Infect. Dis. 15, 215-222 (2009).
17. McFarland LV, Surawicz CM, Greenberg RN et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271, 2913-2918 (1994).
18. Pillai A, Nelson R: Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst. Rev. CD004611 (2008).
19. Hall JF, Berger D: Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am. J. Surg. 196, 284-288 (2008).
20. Lowy I, Molrine DC, Leav BA et al.: Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197-205 (2010).
21. O'Horo J, Safdar N: The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int. J. Infect. Dis. 13, 263-267 (2009).
22. Garey KW, Jiang ZD, Bellard A, DuPont HL: Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J. Clin. Gastroenterol. 43, 21-23 (2009).
23. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ: Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect. Control Hosp. Epidemiol. 31, 21-27 (2010).
24. Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR: Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am. J. Infect. Control. 38(5), 350-353 (2010).
25. Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH: Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J. Antimicrob. Chemother. 65, 208-218 (2010).